Prevalence, predictors and management of left atrial appendage thrombogenic milieu in atrial fibrillation with low thromboembolic risk

Table 4 Management of patients with LAAT or sludge

Patient #	Age (y/o)	Sex	AF type	CHA₂DS₂-VASc score	LAD (mm)	MR	OAC before TEE	LAAT or sludge	LAA SEC	OAC after TEE	LAAT/sludge resolution	Time to resolution (day)
1	61	Male	PeAF	1	57	None	No	LAAT	No	Rivaroxaban 10 mg QD	Yes	141
2	55	Male	PeAF	0	48	None	No	LAAT	No	Rivaroxaban 20 mg QD	Yes	106
3	60	Female	PeAF	1	49	None	No	LAAT	Yes	Dabigatran 110 mg BID	Yes	94
4	48	Male	PeAF	1	48	Moderate	No	LAAT	Yes	VKA (TTR 75%)	Yes	168
5	59	Male	PeAF	1	45	None	No	LAAT	Yes	VKA (TTR 60%)	Yes	84
6	64	Female	PeAF	2	44	Mild	No	LAAT	No	Rivaroxaban 20 mg QD	Yes	140
7	63	Male	PAF	0	42	Mild	Yes	LAAT	No	Rivaroxaban 20 mg QD	Yes	135
8	59	Male	PAF	0	35	None	No	LAAT	Yes	Rivaroxaban 20 mg QD	Yes	102
9	45	Male	PeAF	1	45	None	No	LAAT	No	Rivaroxaban 20 mg QD	Yes	119
10	58	Male	PeAF	1	43	Mild	No	sludge	No	VKA (TTR 67%)	Yes	96
11	58	Male	PAF	1	38	None	No	sludge	No	Rivaroxaban 20 mg QD	Yes	121
12	55	Female	PeAF	2	45	Mild	No	sludge	No	Rivaroxaban 20 mg QD	Yes	104

LAAT, left atrial appendage thrombus; AF, atrial fibrillation; LAD, left atrial diameter; MR, mitral regurgitation; OAC, oral anticoagulant; TEE, transesophageal echocardiography; SEC, spontaneous echo contrast; PAF, paroxysmal atrial fibrillation; PeAF, persistent atrial fibrillation; VKA, Vitamin K antagonist; TTR, time in therapeutic range.

ISSN: 1477-9560